Literature DB >> 17360599

Genetic analysis of the calcineurin pathway identifies members of the EGR gene family, specifically EGR3, as potential susceptibility candidates in schizophrenia.

Kazuo Yamada1, David J Gerber, Yoshimi Iwayama, Tetsuo Ohnishi, Hisako Ohba, Tomoko Toyota, Jun Aruga, Yoshio Minabe, Susumu Tonegawa, Takeo Yoshikawa.   

Abstract

The calcineurin cascade is central to neuronal signal transduction, and genes in this network are intriguing candidate schizophrenia susceptibility genes. To replicate and extend our previously reported association between the PPP3CC gene, encoding the calcineurin catalytic gamma-subunit, and schizophrenia, we examined 84 SNPs from 14 calcineurin-related candidate genes for genetic association by using 124 Japanese schizophrenic pedigrees. Four of these genes (PPP3CC, EGR2, EGR3, and EGR4) showed nominally significant association with schizophrenia. In a postmortem brain study, EGR1, EGR2, and EGR3 transcripts were shown to be down-regulated in the prefrontal cortex of schizophrenic, but not bipolar, patients. These findings raise a potentially important role for EGR genes in schizophrenia pathogenesis. Because EGR3 is an attractive candidate gene based on its chromosomal location close to PPP3CC within 8p21.3 and its functional link to dopamine, glutamate, and neuregulin signaling, we extended our analysis by resequencing the entire EGR3 genomic interval and detected 15 SNPs. One of these, IVS1 + 607A-->G SNP, displayed the strongest evidence for disease association, which was confirmed in 1,140 independent case-control samples. An in vitro promoter assay detected a possible expression-regulatory effect of this SNP. These findings support the previous genetic association of altered calcineurin signaling with schizophrenia pathogenesis and identify EGR3 as a compelling susceptibility gene.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17360599      PMCID: PMC1815264          DOI: 10.1073/pnas.0610765104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  51 in total

1.  Inference of population structure using multilocus genotype data.

Authors:  J K Pritchard; M Stephens; P Donnelly
Journal:  Genetics       Date:  2000-06       Impact factor: 4.562

Review 2.  Calcineurin regulation of neuronal plasticity.

Authors:  Rachel D Groth; Robert L Dunbar; Paul G Mermelstein
Journal:  Biochem Biophys Res Commun       Date:  2003-11-28       Impact factor: 3.575

3.  Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment.

Authors:  V Arolt; M Rothermundt; K P Wandinger; H Kirchner
Journal:  Mol Psychiatry       Date:  2000-03       Impact factor: 15.992

4.  Prefrontal functioning during context processing in schizophrenia and major depression: an event-related fMRI study.

Authors:  Avram J Holmes; Angus MacDonald; Cameron S Carter; Deanna M Barch; V Andrew Stenger; Jonathan D Cohen
Journal:  Schizophr Res       Date:  2005-07-15       Impact factor: 4.939

5.  T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions.

Authors:  Jonathan Kipnis; Hagit Cohen; Michal Cardon; Yaniv Ziv; Michal Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-12       Impact factor: 11.205

6.  Identification of aberrantly methylated genes in association with adult T-cell leukemia.

Authors:  Jun-Ichirou Yasunaga; Yuko Taniguchi; Kisato Nosaka; Mika Yoshida; Yorifumi Satou; Tatsunori Sakai; Hiroaki Mitsuya; Masao Matsuoka
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

7.  Neuregulin induces the expression of transcription factors and myosin heavy chains typical of muscle spindles in cultured human muscle.

Authors:  Christian Jacobson; David Duggan; Gerald Fischbach
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-09       Impact factor: 11.205

8.  Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia.

Authors:  Effat S Emamian; Diana Hall; Morris J Birnbaum; Maria Karayiorgou; Joseph A Gogos
Journal:  Nat Genet       Date:  2004-01-25       Impact factor: 38.330

9.  Axonal neuregulin-1 regulates myelin sheath thickness.

Authors:  Galin V Michailov; Michael W Sereda; Bastian G Brinkmann; Tobias M Fischer; Bernhard Haug; Carmen Birchmeier; Lorna Role; Cary Lai; Markus H Schwab; Klaus-Armin Nave
Journal:  Science       Date:  2004-03-25       Impact factor: 47.728

Review 10.  Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia.

Authors:  Gabriel Corfas; Kristine Roy; Joseph D Buxbaum
Journal:  Nat Neurosci       Date:  2004-06       Impact factor: 24.884

View more
  67 in total

1.  PET neuroimaging reveals histone deacetylase dysregulation in schizophrenia.

Authors:  Tonya M Gilbert; Nicole R Zürcher; Christine J Wu; Anisha Bhanot; Baileigh G Hightower; Minhae Kim; Daniel S Albrecht; Hsiao-Ying Wey; Frederick A Schroeder; Anais Rodriguez-Thompson; Thomas M Morin; Kamber L Hart; Amelia M Pellegrini; Misha M Riley; Changning Wang; Steven M Stufflebeam; Stephen J Haggarty; Daphne J Holt; Marco L Loggia; Roy H Perlis; Hannah E Brown; Joshua L Roffman; Jacob M Hooker
Journal:  J Clin Invest       Date:  2018-12-10       Impact factor: 14.808

2.  Association study of MiRSNPs with schizophrenia, tardive dyskinesia and cognition.

Authors:  Jibin John; Triptish Bhatia; Prachi Kukshal; Puneet Chandna; Vishwajit L Nimgaonkar; Smita N Deshpande; B K Thelma
Journal:  Schizophr Res       Date:  2016-04-19       Impact factor: 4.939

3.  Comprehensive behavioral analysis of calcium/calmodulin-dependent protein kinase IV knockout mice.

Authors:  Keizo Takao; Koichi Tanda; Kenji Nakamura; Jiro Kasahara; Kazuki Nakao; Motoya Katsuki; Kazuo Nakanishi; Nobuyuki Yamasaki; Keiko Toyama; Minami Adachi; Masahiro Umeda; Tsutomu Araki; Kohji Fukunaga; Hisatake Kondo; Hiroyuki Sakagami; Tsuyoshi Miyakawa
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

4.  Comparative Analysis of Gene Expression Profiles Involved in Calcium Signaling Pathways Using the NLVH Animal Model of Schizophrenia.

Authors:  Alma Genis-Mendoza; Ileana Gallegos-Silva; Carlos Alfonso Tovilla-Zarate; Lilia López-Narvaez; Thelma Beatriz González-Castro; Yazmín Hernández-Díaz; Mavil López-Casamichana; Humberto Nicolini; Sandra Morales-Mulia
Journal:  J Mol Neurosci       Date:  2017-12-06       Impact factor: 3.444

5.  Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse.

Authors:  Patrick O McGowan; Aya Sasaki; Ana C D'Alessio; Sergiy Dymov; Benoit Labonté; Moshe Szyf; Gustavo Turecki; Michael J Meaney
Journal:  Nat Neurosci       Date:  2009-03       Impact factor: 24.884

6.  A novel microRNA and transcription factor mediated regulatory network in schizophrenia.

Authors:  An-Yuan Guo; Jingchun Sun; Peilin Jia; Zhongming Zhao
Journal:  BMC Syst Biol       Date:  2010-02-15

7.  Positive association of common variants in CD36 with neovascular age-related macular degeneration.

Authors:  Naoshi Kondo; Shigeru Honda; Shin-Ichi Kuno; Akira Negi
Journal:  Aging (Albany NY)       Date:  2009-02-12       Impact factor: 5.682

8.  Comprehensive behavioral phenotyping of ryanodine receptor type 3 (RyR3) knockout mice: decreased social contact duration in two social interaction tests.

Authors:  Naoki Matsuo; Koichi Tanda; Kazuo Nakanishi; Nobuyuki Yamasaki; Keiko Toyama; Keizo Takao; Hiroshi Takeshima; Tsuyoshi Miyakawa
Journal:  Front Behav Neurosci       Date:  2009-05-07       Impact factor: 3.558

9.  SOD2 gene polymorphisms in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Naoshi Kondo; Hiroaki Bessho; Shigeru Honda; Akira Negi
Journal:  Mol Vis       Date:  2009-09-09       Impact factor: 2.367

10.  Combining gene expression, demographic and clinical data in modeling disease: a case study of bipolar disorder and schizophrenia.

Authors:  Jan Struyf; Seth Dobrin; David Page
Journal:  BMC Genomics       Date:  2008-11-07       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.